Vaginal Sildenafil for Primary Dysmenorrhea

A vizsgálat adatai

Ki végzi

Kevin Hellman

Azonosító

NCT07508358

A regiszteradat frissítve

2026. szeptember 25.

Eredeti leírás

This open-label, non-randomized mechanistic study will evaluate whether a single 100 mg vaginal sildenafil citrate suppository reduces uterine hypercontractility during menstruation in adults with moderate-to-severe dysmenorrhea. Ten participants will each receive one open-label dose during a single menstrual treatment visit and will serve as their own control: 6 participants with primary dysmenorrhea and no evidence of pelvic pathology, plus a separately analyzed exploratory subset of 4 participants, 2 with known endometriosis and 2 with known uterine fibroids. Uterine contractility will be measured with cine magnetic resonance imaging (MRI) before dosing and approximately 4 hours after dosing. Additional objectives are to evaluate acute menstrual pain over the 4-hour observation window, to document systemic exposure using sparse plasma sampling at approximately 2 and 4 hours after dosing, and to assess short-term safety and local tolerability.A teljes eredeti leírásKevesebb

Vaginal Sildenafil for Primary Dysmenorrhea: An Open-Label Mechanistic Study

This open-label, non-randomized mechanistic study will evaluate whether a single 100 mg vaginal sildenafil citrate suppository reduces uterine hypercontractility during menstruation in adults with moderate-to-severe dysmenorrhea. Ten participants will each receive one open-label dose during a single menstrual treatment visit and will serve as their own control: 6 participants with primary dysmenorrhea and no evidence of pelvic pathology, plus a separately analyzed exploratory subset of 4 participants, 2 with known endometriosis and 2 with known uterine fibroids. Uterine contractility will be measured with cine magnetic resonance imaging (MRI) before dosing and approximately 4 hours after dosing. Additional objectives are to evaluate acute menstrual pain over the 4-hour observation window, to document systemic exposure using sparse plasma sampling at approximately 2 and 4 hours after dosing, and to assess short-term safety and local tolerability.

Bevonási feltételek: Female sex assigned at birth; Age 18 to 35 years; History of moderate-to-severe dysmenorrhea; Regular menstrual cycles of approximately 21 to 35 days; Willing and able to complete a single menstrual treatment visit; Able to comply with study procedures, including MRI procedures and vaginal self-administration of study product; Able to provide informed consent.

Kizáró feltételek: Use of any CYP3A4 inhibitor or inducer, including dietary sources such as grapefruit; Use of another phosphodiesterase type 5 inhibitor; Use of any alpha-adrenergic blocker or any antihypertensive medication; Other contraindication to MRI or factors that would impair MRI safety or interpretability, including certain metallic implants, metallic injury, or claustrophobia; Known hypersensitivity to sildenafil or any formulation component; Uncontrolled hypertension, defined as systolic blood pressure at or above 140 mmHg or diastolic blood pressure at or above 90 mmHg; Cardiovascular disease; Severe renal impairment; Bleeding disorder; Peptic ulcer disease; History of non-arteritic anterior ischemic optic neuropathy, risk factors for non-arteritic anterior ischemic optic neuropathy, or other retinal disorders; Sickle cell disease; Active pelvic infection; Any condition that, in the opinion of the investigator, would increase risk or interfere with study participation; Clinically significant laboratory abnormality, as judged by the investigator; Hepatic impairment of any severity, assessed by screening hepatic laboratory testing and clinical history; Platelet count below 100,000 per microliter or hemoglobin below 10 g/dL on screening complete blood count; Gross pelvic pathology identified by clinical history or by the prespecified review of the baseline research MRI. This criterion does not apply to participants enrolled in the prespecified exploratory cohort with known endometriosis or known uterine fibroids, who are analyzed separately; Use of nitrates or nitric oxide donors; Near-hypotension, defined as systolic blood pressure at or below 95 mmHg or diastolic blood pressure at or below 65 mmHg; Clinically significant electrocardiographic abnormality, as judged by the investigator; Presence of an intrauterine device, because of MRI artifact affecting interpretability; Pregnant or breastfeeding.

ClinicalTrials.gov NCT07508358